HPTN 083-A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

Grant

Date/time Interval

  • January 1, 2017 - November 30, 2020
  • Total Award Amount

  • 1195702.00
  • Direct Costs

  • 813403.00
  • Sponsor Award Id

  • PO17001904
  • Contributor

  • Goepfert M.D., Paul   Investigator  
  • Heath, Sonya   Investigator  
  • Overton, Edgar   Principal Investigator